Drug intelligence / Profile preview

indium-111-labeled monoclonal antibody 1A3

Development stage
Unknown
Modality
Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Gamma Emitters → Radiopharmaceuticals, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration
Intravenous
01

Overview

Indium-111-labeled monoclonal antibody 1A3 is a murine monoclonal antibody (MAb 1A3) conjugated with the bifunctional chelating agent N,N'-bis(2-hydroxybenzyl)-1(4-bromoacetamidobenzyl)-1,2-ethylenediamine-N,N'-diacetic acid and radiolabeled with the gamma-emitting isotope indium-111. This radioimmunoconjugate is designed for radioimmunoscintigraphy to detect colorectal carcinoma lesions. MAb 1A3 binds to a lipid antigen enriched in human colon cancer cells, enabling targeted imaging of tumor sites. In clinical studies, it demonstrated high sensitivity for detecting nonhepatic abdominal-pelvic tumors and recurrent rectosigmoid cancer, with a positive predictive value of approximately 83%. The agent is primarily used as an imaging diagnostic tool rather than for therapeutic purposes[1][9][6].

Other names
indium-111-N,N'-bis(2-hydroxybenzyl)1(4-bromoacetamidobenzyl)1,2-ethylenediamine-N,N'-diacetic acid-monoclonal antibody 1A3
02

Targets

1A3 (1A3 antigen)

Beyond the preview

Go deeper on indium-111-labeled monoclonal antibody 1A3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on indium-111-labeled monoclonal antibody 1A3.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call